Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity.

J Immunother Cancer · 2021 · PMC8194333 · PMID 34112738

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, as opposed to Δ133p53α data, the expression of the immune inhibitory molecule TIGIT (and to a lesser extent PD-1) showed a trend toward higher levels.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.